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Abstract (229 words) 
Statin therapy modestly increases new-onset diabetes risk. The effect of PCSK9 inhibition on 
new-onset diabetes, glycemia and weight remains unclear.We studied the effects of the 
PCSK9 inhibitor evolocumab on fasting plasma glucose [FPG], glycated hemoglobin 
(HbA1c), weight and new-onset diabetes mellitus. We pooled 1-year (48-week) data for 
participants who had completed an evolocumab parent study before entering an open-label 
extension (OLE) trial. Data were available for 4,802 participants (1,602 on standard of care 
[SOC]; 3,200 on evolocumab plus SOC) in 2 OLE trials. Evolocumab lowered LDL-
cholesterol by approximately 60% compared to SOC alone. Over the first year of the OLE 
trials, there was no difference in median (Q1, Q3) change in HbA1c (0.1% [–0.1, 0.2] for both 
SOC and evolocumab plus SOC) and FPG (0.06mmol/L [–0.28, 0.38 mmol/L] for SOC and 
0.06mmol/L [–0.28, 0.44 mmol/L] for evolocumab plus SOC). Mean weight change (standard 
error) at 1 year was –0.1kg (0.2) on SOC compared to 0.3kg (0.1) on evolocumab plus SOC. 
The exposure-adjusted incidence rate (95% confidence intervals) for new-onset diabetes per 
100 patient years was 3.7 (2.9-4.7) on control/SOC alone and 3.9 (3.2-4.6) on 
evolocumab/evolocumab plus SOC treatment. Glycemic changes observed in 6,430 
participants at week 12 in the parent studies were comparable to OLE trial findings. In 
conclusion, evolocumab therapy has no effect on glucose homeostasis over 1 year of open-
label treatment. 
Funding: Amgen Inc. 
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Evidence from both randomized clinical trials and studies of genetic polymorphisms 
demonstrates that lowering LDL-cholesterol lowers the risk of cardiovascular events
1
. While 
statin therapy is effective and safe, an adverse effect that has emerged in meta-analyses of 
major trials and studies of genetic polymorphisms is a modest increase in glycated 
hemoglobin (HbA1c) levels and the risk of developing diabetes
2,3
. It remains unclear whether 
this effect reflects the specific mechanism of action of a statin or whether other approaches to 
lowering LDL-cholesterol have the same diabetogenic effect
4,5
. 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein of 
predominantly hepatic origin that reduces the efficacy of hepatic LDL-receptor recycling 
6,7
. 
Twelve-week clinical trials of the monoclonal antibody PCSK9 inhibitor, evolocumab, have 
demonstrated reductions in LDL-cholesterol of around 60% 
8,9
. Two placebo-controlled 
clinical trials have also confirmed a reduction in cardiovascular events by PCSK9 inhibition. 
Results from a single study of 901 participants suggest that evolocumab has no 
notable effect on measures of glycemia and beta cell function
12
 and, in recently published data 
from the FOURIER trial, there was no effect of evolocumab on new-onset diabetes compared 
to placebo over 2.2 years
10
.  However, genetic findings indicate that PCSK9 variants 
associated with lower LDL-cholesterol do increase risk of developing diabetes
14-16
. We 
therefore examined the effect of evolocumab therapy over 1 year in 2 open-label extension 
(OLE) studies to determine if this agent has any notable effect on measures of glycemic 
control, weight, or new-onset diabetes. These 2 OLE studies enrolled participants who had 
previously completed a qualifying evolocumab parent study. 
 
Methods 
 Thirteen parent trials
17-28
 fed into the 2 ongoing open-label extension (OLE) 
randomized controlled trials, OSLER-1 and OSLER-2
29
 (see Supplementary Table 1). 
Eleven out of the 13 parent studies were randomized trials that compared evolocumab to 
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placebo or ezetimibe (one was a 52-week trial
21
 while the remaining 10 were 12-week trials). 
In the other 2 parent studies (6 weeks and 12 weeks), participants only received evolocumab.        
At the end of the parent trials, participants had the option to continue into an OLE 
trial. Those who opted to do so were randomized in a 2:1 ratio to evolocumab plus standard of 
care (SOC) or to SOC alone for the first year of the OLE trial without regard to treatment 
allocation in the parent trial. Analyses of the OLE trials were limited to the first year; 
following the first year, all randomized participants were offered open-label evolocumab for 
the remainder of the study. In these OLE trials, background statin therapy could vary as 
determined by the treating physician. Participants from the parent trials plus the OLE trials 
provided written informed consent and the trials were approved by all relevant ethics 
committees and regulatory bodies. Key eligibility criteria for the parent and OLE trials, 
including specific exclusion criteria related to diabetes, are provided in Supplementary 
Table 1. For the parent trials, the safety population was defined as all randomized participants 
who received at least 1 dose of study drug. For the OLE trials, the safety population was 
defined as all randomized participants. Randomization sequences were generated by computer 
for the trials by the sponsor, Amgen. In OSLER-1, randomization was stratified by treatment 
arm in the parent study, while in OSLER 2 it was stratified by parent study and frequency of 
subcutaneous dosing. Each trial was overseen by an independent data monitoring committee.  
The main purpose of this analysis was to investigate the effect of 1-year of open-label 
evolocumab compared to control therapy on glycemia, body weight, and new-onset diabetes 
mellitus. Evolocumab was administered by subcutaneous injection either in the clinic or by 
self-administration at the participant’s home. All participants entering an OLE study were 
randomized to receive either evolocumab plus SOC or SOC alone in a 2:1 ratio.  Evolocumab 
was administered at a dose of 420 mg once a month in OSLER-1 and, based on participant 
choice, at a dose of either 140 mg every 2 weeks or 420 mg once a month in OSLER-2.  The 
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2 regimens have been shown to be clinically equivalent. Lipid data from biweekly and 
monthly dosing regimens for evolocumab were similar and were therefore pooled in this 
analysis. Blood samples were taken at baseline, 12, 24 and 48 weeks to measure fasting (>9 
hours) lipids, FPG and HbA1c at a central laboratory (Medpace Reference Laboratories, 
Cincinnati, USA and Leuven, Belgium). LDL-cholesterol was determined by the Friedewald 
formula (LDL-cholesterol [mmol/L] = total cholesterol [mmol/L] – HDL-cholesterol 
[mmol/L] – triglycerides [mmol/L]/2.2). In OSLER-1 weight was measured at baseline and 52 
weeks whereas in OSLER-2 weight was measured at baseline and 48 weeks. 
To determine if there was any confounding due to parent-study effects, changes in 
glycemia were examined over the parent-study period in the parent trials of evolocumab. We 
also compared participants who did or did not enrol in an OSLER trial following completion 
of a parent study to rule out differences and possible confounding.  The methodology applied 
in the parent trials was very similar to the approach taken in the OLE trials (see 
Supplementary information). 
 T2DM at baseline was defined as medical history of diabetes, baseline HbA1c ≥6.5% 
(48 mmol/mol), baseline fasting plasma glucose ≥7.0 mmol/L, or use of medication for 
T2DM. New-onset T2DM during follow-up was defined as any of the following: a diabetes 
adverse event (AE), at least a single HbA1c ≥6.5% (48 mmol/mol), 2 consecutive fasting 
plasma glucose values ≥7.0 mmol/L, or newly commenced use of medication for an 
indication of T2DM. High risk of diabetes was defined as impaired fasting glycemia (i.e. FPG 
6.1–6.9mmol/L) or HbA1c ≥6.0% at baseline, and not meeting the criteria for T2DM. 
 Baseline laboratory values for variables of interest in the OLE trials were taken from 
the baseline values in the parent trials. Continuous variables are presented as mean (standard 
deviation) or median (25
th
, 75
th
 percentiles), as appropriate. Percent change in LDL-
cholesterol was calculated for each subject as 100* (week 48 – baseline) / baseline. The mean 
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percent change in LDL-cholesterol was calculated across trials without modelling. Changes in 
weight, FPG and HbA1c were compared between those randomized to evolocumab plus SOC 
and those randomized to SOC alone in the OLE trials. Safety analyses were conducted using 
descriptive statistics. Descriptive statistics were provided for absolute values as well as 
changes from baseline in laboratory parameters. Parent studies and the analysis reported here 
were not powered for safety endpoints; therefore, AEs and safety measures are summarized 
descriptively without inferential statistical analyses (or corresponding P values). Comparisons 
were made between all participants in each treatment arm and also for the following 
subgroups: those with diabetes, those without diabetes and those at high risk of diabetes. 
In supportive analyses we compared the effect of evolocumab to control therapy at 12 
weeks in the parent studies. Given the possibility that there may have been bias in progression 
from parent trials to OLE trials based on randomized treatment in the parent trial, we 
performed a sensitivity analysis to determine whether there were differences between 
participants who did or did not enrol in an OSLER trial following a parent study.  
We also calculated the exposure-adjusted incidence rate per 100 patient years for new onset 
diabetes, from randomization in the parent trials until the end of year 1 in the OLE trials. Data 
were analysed using SAS version 9.3. Amgen funded the parent trials and OLE trials, which 
were designed in collaboration with each trial’s investigators. The lead co-authors (N.S., 
P.P.T. and D.P.) proposed the study and developed the analyses in collaboration with co-
authors M.E. and R.S. Amgen was responsible for data collection and analysis. 
 
Results 
There were 6,430 participants in the parent trials (4,148 participants randomized to 
evolocumab and 2,282 to control therapy). Baseline characteristics for participants in the 
parent trials are provided in Supplementary Table 2. Of the 6,430 participants in the parent 
trials, 4,802 (75% consisting of 1,602 participants randomized to SOC and 3,200 to 
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evolocumab plus SOC) enrolled in an OLE trial. For these participants at baseline, median 
HbA1c was 5.6% for SOC and 5.6% for evolocumab; median FPG was 5.4mmol/L for SOC 
alone and 5.4mmol/L for evolocumab; and 18.0% (SOC) and 17.6% (evolocumab) had 
diabetes respectively (Table 1). Mean LDL-cholesterol was 3.3mmol/L for SOC and 
3.3mmol/L for evolocumab plus SOC. Evolocumab plus SOC lowered LDL-cholesterol by 
50-60% over 48 weeks (Table 2 and Figure 1A) compared with SOC alone. 
Pooled data at 12, 24 and 48 weeks is presented for FPG in Figure 1B and for HbA1c 
in Figure 1C. Change in median HbA1c was identical over 48 weeks in both treatment arms, 
namely 0.1%. Change in median FPG was also very similar between treatment arms over 48 
in the analysis of all participants: 0.06mmol/L on evolocumab plus SOC compared to 
0.06mmol/L on SOC alone. Subgroup analyses for those with diabetes, without diabetes and 
at high risk of diabetes were consistent with this lack of effect (Table 2). Results at week 12 
in a pooled analysis of the 13 parent studies feeding into the OLE trials were consistent with 
the 1 year OLE results (Supplementary Table 3). There was also no difference in change in 
FPG or HbA1c during the parent trials for those who did (n=4,802) or did not (n=1,628) 
subsequently proceed from a parent trial into an OLE trial (Supplementary Table 3).  
Mean weight change during the OLE trials was 0.3kg on evolocumab plus SOC over 
48-52 weeks compared with –0.1kg on SOC alone in an analysis of all participants (Table 2). 
In those with diabetes, mean weight change was –0.4kg in participants with evolocumab plus 
SOC and –0.6kg in participants receiving SOC alone. In participants without diabetes, mean 
weight change was 0.4kg in participants with evolocumab plus SOC, and was 0.0kg in 
participants on SOC alone). In participants at high risk for diabetes, mean change in weight 
was 0.1kg in participants on evolocumab and 0.2kg in participants on SOC alone. 
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Of those without diabetes at parent-study baseline, the exposure-adjusted incidence of 
new-onset diabetes per year was 3.85 cases per 100 patient-years on evolocumab/evolocumab 
plus SOC treatment and 3.69 cases per 100 patient-years on control/SOC alone (Table 3).  
 
Discussion 
While statins modestly increase the risk of developing diabetes mellitus and recent 
genetic data suggest a potential link between PCSK9 genes and diabetes risk
14
, we 
demonstrate that 1 year of treatment with evolocumab in an OLE setting does not increase 
HbA1c, fasting glucose or diabetes risk in comparison to SOC. We also provide novel data 
for weight change and these results are also broadly reassuring. These results in conjunction 
with randomized data for evolocumab from the FOURIER
10
 and DESCARTES trials
12
, for 
alirocumab from the ODYSSEY program
13
, and for bococizumab from the SPIRE trials
11
 
suggest PCSK9 inhibition is unlikely to have any clinically relevant effect on glycemia.   
A recently published analysis that combined information from several PCSK9 
polymorphisms suggested a potentially causal link between PCSK9 inhibition and diabetes 
risk
14
. The same publication also linked polymorphisms in the NPC1L1 gene (related to 
ezetimibe therapy) with increased diabetes risk, implying that multiple LDL-cholesterol 
reducing pathways may enhance diabetes risk, a hypothesis reinforced by genetic analyses of 
LDL-cholesterol and diabetes risk
5
. Even when causative relationships are identified, 
extrapolation to what size of effects may be seen with therapeutic interventions (in this case 
PCSK9 inhibition with monoclonal antibodies) is problematic given that genetic effects are 
present throughout the lifespan and drug effects may not fully or precisely influence the 
pathways influenced by genes. This reinforces the need for randomized clinical trials of an 
intervention to reliably confirm or refute any impact on an outcome of interest. Recently 
published data from major cardiovascular outcome trials have confirmed that PCSK9 
inhibition translates into a reduction in cardiovascular events in high risk patients and that the 
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benefit is comparable to observations from the major statin trials
10,11
. In addition, these trials 
have shown no effect of PCSK9 inhibitors on new-onset diabetes, though follow-up was 
relatively short. The SPIRE trials revealed a small increase in fasting glucose at 1 year but no 
change in HbA1c. Taken together, data from these trials together with findings in this report 
are thus reassuring and they effectively rule out any clinically significant medium-term effect 
of PCSK9 inhibition on measures of glycemia and new-onset diabetes risk. Participants in the 
evolocumab plus SOC group had a slight increase in weight; however, when we examined 
subgroups, we found that these changes were driven mostly by participants without diabetes 
and not at high risk for diabetes. As the OSLER studies were open-label trials where patients 
and their physicians saw on-label treatment LDL-cholesterol levels, we cannot exclude that a 
reduction in LDL-C led to more liberal caloric intake by patients receiving evolocumab. 
We acknowledge several limitations in our analysis. First, in the OLE trials 
evolocumab was compared to SOC rather than placebo. Nevertheless, given the potency of 
LDL-cholesterol reduction with evolocumab along with analysis of objectively measured 
outcomes, our analyses should be robust. The trials were also relatively short and we therefore 
acknowledge that we cannot rule out longer-term effects on glycemia. Reassuringly, however, 
the modest effect of statins on glycemia in patients with diabetes appears most obvious within 
the first year with little if any deterioration thereafter
30
. Furthermore, length of exposure to 
evolocumab during the parent-study phase differed between participants, due to both parent-
study treatment assignment and parent-study length. We acknowledge that the number of 
cases of new-onset diabetes was relatively small in our study compared to the FOURIER trial; 
however, the current results provide detailed information for glycemia and weight for 
evolocumab not available elsewhere. Finally, our work represents a post hoc analysis.   
In summary, treatment with evolocumab in a 1-year, OLE setting had no apparent 
effect on glucose homeostasis.  
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Figure Legends:  
 
Figure 1. The effect of open-label evolocumab with standard care versus standard care alone 
on (A) LDL-cholesterol (B) fasting plasma glucose, and (C) HbA1c for up to 48 weeks. Error 
bars indicate 1 standard error. 
 
Footnote: Abbreviations: EOS: end of study; Evo, evolocumab; HbA1c, glycated 
hemoglobin; LDL-C, low-density lipoprotein cholesterol; SE, standard error; SOC, standard 
of care 
 
Table 1. Baseline demographics for patients entering 48-week OSLER studies* 
Variable SOC Alone 
(N = 1602) 
Evolocumab + SOC 
(N = 3200) 
Age (years), mean (SD) 58.4 ± 10.9 58.0 ±  11.0 
Men 831 (51.9%) 1629 (50.9%) 
White 
Asian 
Black/African American 
Other race 
1267 (79.1%) 
236 (14.7%) 
72 (4.5%) 
27 (1.7%) 
2559 (80.0%) 
455 (14.2%) 
135 (4.2%) 
51 (1.6%) 
Hypertension 857 (53.5%) 1711 (53.5%) 
Type 2 diabetes mellitus† 289 (18.0%) 563 (17.6%) 
High risk of diabetes‡ 494 (30.8%) 1023 (32.0%) 
Current smoker 248 (15.5%) 520 (16.3%) 
Coronary artery disease** 319 (19.9%) 610 (19.1%) 
Cerebrovascular  or peripheral 
arterial disease 156 (9.7%) 291 (9.1%) 
LDL-cholesterol (mmol/L) 
LDL-cholesterol (mg/dL) 
3.3 ± 1.2 
127.0 ± 44.9 
3.3 ±  1.1 
126.3 ± 44.3 
Hemoglobin-A1c (%)§ǁ 5.6 (5.3, 5.9) 5.6 (5.3, 6.0) 
Fasting plasma glucose (mmol/L)§ 
Fasting plasma glucose (mg/dL)§ 
5.4 (5.1, 5.9) 
 
98.0 (91.0, 107.0) 
5.4 (5.1, 5.9) 
98.0 (91.0, 107.0) 
SOC: standard of care 
Data shown as mean ± SD, or count (%) 
* Parent-study baseline 
† Defined as previously known T2DM, on glucose-lowering medication, baseline FPG ≥7.0 mmol/L 
or baseline HbA1c ≥6.5% 
**History of angina, myocardial infarction, coronary artery bypass graft or percutaneous coronary 
intervention 
‡ Impaired fasting glucose (i.e. fasting plasma glucose 6.1–6.9mmol/L) or HbA1c ≥6.0% at baseline, 
and not meeting the criteria for T2DM 
§ Median (Q1, Q3) 
ǁ Available for 1327 participants assigned to SOC alone and 2685 assigned to evolocumab + SOC 
  
Table 2. Changes in Low Density Lipoprotein-cholesterol, fasting plasma glucose, Hemoglobin-A1c and weight over 48-52 weeks in the OSLER-1 and 
OSLER-2 trials 
 
Visit 
LDL-C in mmol/L (baseline: 
mean (SD) [n]; wk 48 and 
change: mean (SE) [n]) 
Fasting plasma glucose in 
mmol/L (median (Q1, Q3) [n]) 
HbA1c in % (median (Q1, Q3) 
[n]) 
Weight in kg (baseline: mean (SD) 
[n]; wk 48 and change: mean (SE) 
[n]) 
  
SOC 
EvoMab + 
SOC 
SOC 
EvoMab + 
SOC 
SOC 
EvoMab + 
SOC 
SOC EvoMab + SOC 
All 
Baseline  
3.3 ± 1.2 
[1602] 
3.3 ± 1.1 
[3200] 
5.4 (5.1, 5.9) 
[1602] 
5.4 (5.1, 5.9) 
[3200] 
5.6 (5.3, 5.9) 
[1327] 
5.6 (5.3, 6.0) 
[2685] 
83.1 ± 18.3 
[1274] 
83.0 ± 17.8 
[2521] 
Week 48* 
3.4 ± 0 
[1219] 
1.5 ± 0 
[2508] 
5.5 (5.1, 6.0) 
[1261] 
5.5 (5.1, 6.0) 
[2561] 
5.6 (5.4, 5.9) 
[1260] 
5.6 (5.4, 5.9) 
[2555] 
83.0 ± 0.5 
[1274] 
83.3 ± 0.4 
[2521] 
Change to 
Week 48* 
0 ± 0 
[1219] 
-1.8 ± 0 
[2508] 
0.1 (-0.3, 0.4) 
[1261] 
0.1 (-0.3, 0.4) 
[2561] 
0.1 (-0.1, 0.2) 
[1017] 
0.1 (-0.1, 0.2) 
[2079] 
-0.1 ± 0.2 
[1274] 
0.3 ± 0.1 
[2521] 
Diabetes 
Baseline  
3.0 ± 1.0 
[289] 
3.0 ± 0.9 
[563] 
6.9 (6.0, 8.2) 
[289] 
6.9 (5.9, 7.9) 
[563] 
6.5 (6.1, 7.1) 
[278] 
6.5 (6.1, 7.1) 
[542] 
89.3 ± 21.1 
[198] 
88.3 ± 20.4 
[367[ 
Week 48* 
3.1 ± 0.1 
[183] 
1.3 ± 0 
[352] 
6.9 (5.9, 8.2) 
[194] 
6.8 (6.0, 7.9) 
[363] 
6.5 (6.0, 7.2) 
[194] 
6.5 (6.1, 7.1) 
[364] 
88.7 ± 1.5 
[198] 
87.8 ± 1.1 
[367] 
Change to 
Week 48* 
0 ± 0.1 
[183] 
-1.8 ± 0.1 
[352] 
0.1 (-0.6, 0.9) 
[194] 
0.2 (-0.7, 1.0) 
[363] 
0.1 (-0.1, 0.4) 
[183] 
0.1 (-0.2, 0.5) 
[344] 
-0.6 ± 0.4 
[198] 
-0.4 ± 0.3 
[367] 
No 
Diabetes 
Baseline  
3.4 ± 1.2 
[1313] 
3.3 ± 1.2 
[2637] 
5.3 (5.0, 5.7) 
[1313] 
5.3 (5.0, 5.7) 
[2637] 
5.5 (5.3, 5.7) 
[1049] 
5.5 (5.3, 5.7) 
[2143] 
81.9 ± 17.5 
[1076] 
82.1 ± 17.2 
[2154] 
Week 48* 
3.4 ± 0 
[1036] 
1.5 ± 0 
[2156] 
5.4 (5.1, 5.8) 
[1067] 
5.4 (5.0, 5.8) 
[2198] 
5.6 (5.3, 5.8) 
[1066] 
5.5 (5.3, 5.8) 
[2191] 
82.0 ± 0.5 
[1076] 
82.5 ± 0.4 
[2154] 
Change to 
Week 48* 
0 ± 0 
[1036] 
-1.8 ± 0 
[2156] 
0.1 (-0.2, 0.4) 
[1067] 
0.1 (-0.2, 0.4) 
[2198] 
0.1 (-0.1, 0.2) 
[834] 
0.1 (-0.1, 0.2) 
[1735] 
0.0 ± 0.2 
[1076] 
0.4 ± (0.1 
[2154] 
  
High risk 
of diabetes 
Baseline  
3.3 ± 1.1 
[494] 
3.2 ± 1.1 
[1023] 
5.8 (5.6, 6.1) 
[494] 
5.8 (5.7, 6.1) 
[1023] 
5.7 (5.4, 6.0) 
[410] 
5.7 (5.4, 6.0) 
[843] 
84.1 ± 17.6 
[403] 
86.0 ± 17.0 
[827] 
Week 48*† 
3.3 ± 0.1 
[386] 
1.4 ± 0 
[828] 
5.8 (5.4, 6.2) 
[400] 
5.8 (5.4, 6.2) 
[844] 
5.7 (5.5, 6.0) 
[400] 
5.7 (5.5, 6.0) 
[842] 
84.2 ± 0.9 
[403] 
86.1 ± 0.6 
[827] 
Change to  
Week 48*† 
0 ± 0 
[386] 
-1.8 ± 0 
[828] 
-0.1 (-0.4, 0.3) 
[400] 
-0.1 (-0.4, 0.3) 
[844] 
0.0 (-0.1, 0.2) 
[325] 
0.0 (-0.1, 0.2) 
[672] 
0.2 ± 0.2 
[403] 
0.1 ± 0.2 
[827] 
SOC: standard of care; EvoMab: evolocumab; SD: standard deviation; SE: standard error; wk: week 
* For columns reporting weight data, data are taken from week 48 in OSLER-2 and week 52 in OSLER-1 
† Subset of those with no diabetes, defined as: impaired fasting glucose (i.e. FPG 6.1–6.9 mmol/L) or HbA1c ≥6.0% at baseline, and not meeting the 
criteria for T2DM  
To convert glucose to mg/dL, multiply by 18; to convert LDL-cholesterol to mg/dL, multiply by 38.6 
 
Table 3. Exposure-Adjusted Annual Event Rate for New-Onset Diabetes Mellitus* 
 
 Control/Standard of 
care 
(n = 1359) 
Evolocumab/Evolocumab 
 
(n = 2591) 
New-onset diabetes from start of parent 
study through year one of OSLER 
     Total Patient Years 
     Total Events 
     Exposure-adjusted incidence rate per 100 
patient years (95% confidence intervals) 
 
 
1682.2 
62 
3.7 (2.9-4.7) 
 
 
3297.8 
127 
3.9 (3.2-4.6) 
*Defined as post-baseline commencement of glucose-lowering therapy, a diabetes adverse event, 
HbA1c ≥ 6.5%, or two consecutive fasting plasma glucose values ≥ 7.0mmol/L  
 
  
Figure 1. 
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SUPPLEMENTARY INFORMATION 
 
METHODS 
Parent trial analysis 
Data were pooled from 13 parent studies (Supplementary Table 1). Patients, study personnel, 
investigators, and Amgen study staff were blinded to treatment assignment within dose 
frequency groups of the parent trials. Blood samples were taken at baseline and week 12. 
 
Data from the 12-week parent trials were pooled and analysed together. Exposure to Evolocumab 
or control during the parent study was included in the exposure-adjusted new-onset diabetes 
analysis. Changes in FPG and HbA1c in the parent study were compared between those 
receiving evolocumab and those receiving control. For change in LDL-cholesterol in the parent 
trials, the control group was further divided into those allocated placebo and ezetimibe 
respectively. 
 
SUPPLEMENTARY RESULTS 
Parent trial results 
Baseline data for parent-study patients is provided in Supplementary Table 2. Over 12 weeks, 
evolocumab lowered LDL-C by about 40% compared to ezetimibe and by about 60% compared 
to placebo (Supplementary Table 3). There was no difference in change in FPG or HbA1c over 
this time period in the analysis of all participants. Median change in HbA1c was 0.0% 
(interquartile range [IQR] –0.1, 0.2) on control and 0.0% (IQR –0.1, 0.1) on evolocumab while 
median change in FPG was 0.00mmol/L (IQR –0.02, 0.02) on control and 0.06mmol/L (IQR –
0.3, 0.4) on evolocumab. Results in the subgroups with diabetes, without diabetes and at high 
2 
 
risk of diabetes were entirely consistent with this null overall effect (Supplementary Table 3). 
Maximal change in FPG was 0.06mmol/L and in HbA1c was 0.1% in any of these subgroups. 
Similarly, there was no difference in change in FPG or HbA1c for those who did (n=4,802) or 
did not (n=1,628) proceed from a parent trial to an OLE trial (Supplementary Table 3). 
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Supplementary Table 1. Parent studies enrolling into OSLER-1 or OSLER-2 
 
 Study Acronym Eligibility Criteria Duration Treatment Arms Background Statin N Associated 
Publication 
1 Reduction of LDL-C 
with PCSK9 inhibition in 
Heterozygous Familial 
Hypercholesterolemia 
Disorder Study 
RUTHERFORD Heterozygous FH with LDL-
C ≥2.6mmol/L 
[Patients with type 1 diabetes or 
newly diagnosed or poorly 
controlled (HbA1c >8.5%) type 2 
diabetes excluded] 
12 weeks 3 treatment groups: Evolocumab 350 
mg, 420 mg, or placebo QM 
Statin ± ezetimibe 167 Raal et al. 
2012 
Circulation 
2 Goal Achievement After 
Utilizing an Anti-PCSK9 
Antibody in Statin 
Intolerant Subjects 
GAUSS Statin-intolerant patients, LDL-
C ≥2.6mmol/L  
[Patients with type 1 diabetes or 
poorly controlled or recently 
diagnosed type 2 diabetes excluded] 
12 weeks 5 treatment groups: Evolocumab 280 
mg, 350 mg, or 420 mg QM, OR 
Ezetimibe 10 mg plus SC placebo QM 
OR Ezetimibe 10 mg plus 
evolocumab 420 mg QM 
No/low-dose statin 157 Sullivan et al. 
2012 JAMA 
3 Monoclonal antibody 
against PCSK9 to reduce 
Elevated LDL-C in 
subjects currently Not 
receiving Drug therapy 
for Easing Lipid levels 
MENDEL LDL-C ≥2.6 and < 4.9mmol/L; 
Patients with CAD were excluded. 
[Diabetes mellitus or fasting plasma 
glucose at screening ≥7.0mmol/L or 
HbA1c ≥6.5% excluded] 
 
12 weeks 9 treatment groups:Evolocumab 70 
mg, 105 mg, or 140 mg or placebo 
Q2W OR Evolocumab 280 mg, 350 
mg, or 420 mg or placebo QM OR 
Daily ezetimibe 10 mg 
None 406 Koren et al. 
2012 Lancet 
4 LAPLACE-TIMI 57: 
LDL-C Assessment wtih 
PCSK9 monoclonaL 
Antibody inhibition 
Combined with statin 
thErapy   
LAPLACE-TIMI 
57 
LDL-C ≥2.2 mmol/L 
[Patients with type 1 diabetes or 
newly diagnosed or poorly 
controlled (HbA1c >8.5%) type 2 
diabetes excluded] 
 
12 weeks 8 treatment groups: Evolocumab 70 
mg, 105 mg, 140 mg, or placebo Q2W 
OR Evolocumab 280 mg, 350 mg, 
420 mg, or placebo QM 
Statin ± ezetimibee 629 Giugliano et 
al. 2012 
Lancet 
5 Durable Effect of PCSK9 
antibody CompARed 
wiTh placEbo Study 
DESCARTES LDL-C ≥1.9mmol/L  
Excluded: LDL-C ≤2.6mmol/L with 
CAD or risk equivalent and not 
receiving a statin 
[Patients with type 1 diabetes or 
newly diagnosed type 2 diabetes 
(within 6 months of randomization 
or new screening fasting plasma 
glucose ≥7.0mmol/L] or HbA1c 
≥6.5%), or poorly controlled type 2 
diabetes (HbA1c >8.5%) were 
excluded]  
52 weeks Background lipid-lowering therapy 
stabilized; patients then randomized to 
one of 5 treatment groups: 
evolocumab 420 mg every month, or 
diet alone, or diet + atorvastatin 10 
mg per day, or diet + atorvastatin 80 
mg per day, or  diet + atorvastatin 80 
mg + ezetimibe 10 mg per day 
Lipid-lowering 
therapy, ranging 
from diet alone to 
atorvastatin 80 mg 
plus ezetimibe, was 
optimized to reach 
NCEP ATP III 
LDL-C treatment 
goals 
 
901 Blom et al. 
2014 NEJM 
6 Monoclonal antibody 
against PCSK9 to reduce 
elevated LDL-C in 
subjects currently not 
receiving drug therapy 
for easing lipid levels-2 
MENDEL-2 LDL-C ≥2.6 and <4.9mmol/L 
[Patients with diabetes were 
excluded] 
12 weeks 6 treatment groups: evolocumab 140 
mg Q2W + oral placebo, evolocumab 
420 mg QM + oral placebo, oral 
ezetimibe + SC placebo Q2W,  
ezetimibe + SC placebo QM, or oral 
placebo + SC placebo Q2W, or oral 
placebo + SC placebo QM 
None 614 Koren et al. 
2014 JACC 
4 
 
7 LDL-C assessment w/ 
PCSK9 monoclonal 
antibody inhibition 
combined with statin 
therapy-2  
LAPLACE-2 ≥4.0mmol/L and on no statin  
≥2.6mmol/L and on non-intensive 
statin  
≥2.1mmol/L and on intensive statin 
[Patients with type 1 diabetes or 
newly diagnosed or poorly 
controlled (HbA1c >8.5%) type 2 
diabetes excluded] 
 
12 weeks 24 treatment groups: 
 
Background atorvastatin 80 mg plus 
one of the following: 
 evolocumab 140 mg Q2W + 
placebo QD PO or 
 ezetimibe QD PO + placebo SC 
Q2W or 
 placebo PO + placebo SC Q2W or  
 evolocumab 420 mg QM + placebo 
QD PO or 
 ezetimibe QD PO + placebo SC 
QM or 
 placebo PO + placebo SC QM or 
 
OR 
 
Background rosuvastatin 40 mg plus 
one of the following: 
 evolocumab 140 mg Q2W + 
placebo QD PO or 
 ezetimibe QD PO + placebo SC 
Q2W or 
 placebo PO + placebo SC Q2W or  
 evolocumab 420 mg QM + placebo 
QD PO or 
 ezetimibe QD PO + placebo SC 
QM or 
 placebo PO + placebo SC QM or 
 
OR 
 
Background atorvastatin 10 mg plus 
one of the following: 
 evolocumab 140 mg Q2W + 
placebo QD PO or 
 placebo PO + placebo SC Q2W or  
 evolocumab 420 mg QM + placebo 
QD PO or 
 placebo PO + placebo SC QM or 
 
OR 
 
Background rosuvastatin 5 mg plus 
one of the following: 
 evolocumab 140 mg Q2W + 
placebo QD PO or 
 placebo PO + placebo SC Q2W or  
 evolocumab 420 mg QM + placebo 
5 background statin 
regimens: 
atorvastatin 80mg, 
atorvastatin 10 mg, 
rosuvastatin 40 mg, 
rosuvastatin 5 mg, 
or simvastatin 40 
mg 
1896 Robinson et 
al. 2014 
JAMA 
5 
 
QD PO or 
 placebo PO + placebo SC QM or 
 
OR 
 
Background simvastatin 40 mg plus 
one of the following: 
 evolocumab 140 mg Q2W + 
placebo QD PO or 
 placebo PO + placebo SC Q2W or  
 evolocumab 420 mg QM + placebo 
QD PO or 
 placebo PO + placebo SC QM or 
8 Goal achievement after 
utilizing an anti-PCSK9 
antibody in statin 
intolerant subjects -2   
GAUSS-2 Not at LDL-C goal per NCEP ATP 
III risk categories for fasting LDL-
C, statin intolerant 
[Patients with type 1 diabetes or 
newly diagnosed type 2 diabetes 
(within 6 months of randomization 
or new screening fasting plasma 
glucose ≥7.0mmol/L] or HbA1c 
≥6.5%), or poorly controlled type 2 
diabetes (HbA1c >8.5%) were 
excluded]  
12 weeks 4 treatment groups: placebo SC Q2W 
or QM, evolocumab 140 mg Q2W or 
420 mg QM 
None 307 Stroes et al. 
2014 JACC 
9 Reduction of LDL-C 
with PCSK9 inhibition in 
heterozygous familial 
hypercholesterolemia 
disorder study-2   
RUTHERFORD-2 LDL-C ≥2.6mmol/L, FH 
[no diabetes-based exclusion 
criteria] 
12 weeks 4 treatment groups: 
Evolocumab 140 mg or placebo Q2W, 
or evolocumab 420 mg or placebo 
QM, 
On stable 
background lipid-
lowering therapy for 
at least 4 weeks 
329 Raal et al. 
2015 Lancet 
10 A Double-blind, 
Randomized, Placebo-
controlled, Multicenter 
Study to Evaluate 
Tolerability and Efficacy 
of Evolocumab (AMG 
145) in Japanese Subjects 
YUKAWA LDL-C ≥3.0mmol/L 
[Patients with recently diagnosed 
(i.e. less than 3 months) or poorly 
controlled type 2 diabetes mellitus 
12 weeks 6 treatment groups: 
Placebo SC Q2W, evolocumab 70 mg 
SC Q2W, evolocumab 140 mg SC 
Q2W, placebo SC QM, evolocumab 
280 mg SC QM, evolocumab 420 mg 
SC QM 
On stable statin 
therapy (with or 
without ezetimibe) 
for ≥ 4 weeks prior 
to LDL-C screening 
307 Hirayama et 
al. 2014 Circ J 
11 A Double-blind, 
Randomized, Placebo-
controlled, Multicenter 
Study to Evaluate Safety, 
Tolerability and Efficacy 
of AMG 145 on LDL-C 
in Combination With 
Statin Therapy in 
Japanese Subjects With 
Cardiovascular Risk and 
With Hyperlipidemia or 
Mixed Dyslipidemia 
YUKAWA-2 LDL-C ≥2.6mmol/L  
[Patients with type 1 diabetes, 
newly diagnosed (within 3 months 
prior to randomization) type 2 
diabetes or poorly controlled type 2 
diabetes were excluded] 
12 weeks 8 treatment groups: 
Background atorvastatin 5 or 20 
mg/day for 4 weeks, followed by 
evolocumab 140 mg SC Q2W, 420 
mg SC QM, placebo SC Q2W, or 
placebo SC QM 
On stable statin for 
≥4 weeks before 
LDL-C screening, 
without need for 
uptitration 
404 Kiyosue et al. 
2016 Am J 
Cardiol 
12 Study to Assess In-home 
Use of Evolocumab 
THOMAS-1 LDL-C ≥2.2mmol/L 
[Patients with type 1 diabetes, 
6 weeks Evolocumab 140 mg SC Q2W On stable statin for 
≥4 weeks before 
149 Dent et al. 
2016 
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(AMG 145) Using a 
Prefilled Syringe or a 
Prefilled 
Autoinjector/Pen 
uncontrolled or recently-diagnosed 
type 2 diabetes were excluded] 
LDL-C screening SpringerPlus 
13 A randomized, multi-
center clinical study in 
subjects with 
hypercholesterolemia or 
mixed dyslipidemia 
THOMAS-2 LDL-C ≥2.2mmol/L 
[Patients with type 1 diabetes, 
uncontrolled or recently-diagnosed 
type 2 diabetes were excluded] 
12 weeks Evoocumab 420 mg SC QM On stable statin for 
≥4 weeks before 
LDL-C screening 
164 See above. 
Published 
with 
THOMAS-1 
CAD: coronary artery disease; LDL: low density lipoprotein; FH: familial hypercholesterolemia; PCSK9: proprotein convertase 
subtilisin/kexin type 9; NCEP ATP III: National Cholesterol Education Program Expert Panel on Detection, Evaluation, and 
Treatment of High Blood. Cholesterol in Adults; Q2W: every two weeks; QM: monthly ; SC: subcutaneous 
 
 
 
7 
 
 
Supplementary Table 2. Baseline demographics for parent trials of evolocumab 
 
Characteristic   Any control 
(n = 2282) 
Any EvoMab 
(n = 4148) 
Age  57.6 ±  11.1 57.9 ± 11.3 
Male   1122 (49.2%) 2104 (50.7%) 
Race* White 1753 (76.8%) 3270 (78.8%) 
 Asian 386 (16.9%) 557 (13.4%) 
 Black / African 
American 
106 (4.6%) 248 (6.0%) 
 Other race 37 (1.6%) 72 (1.8%) 
Hypertension  1156 (50.7%) 2241 (54.0%) 
Type 2 diabetes†  387 (17.0%) 720 (17.4%) 
High risk of diabetes‡  686 (30.1%) 1328 (32.0%) 
Current smoker  371 (16.3%) 636 (15.3%) 
Coronary artery disease  372 (16.3%) 821 (19.8%) 
Cerebrovascular disease or 
peripheral arterial disease 
 182 (8.0%) 381 (9.2%) 
LDL-cholesterol (mmol/L) 
LDL-cholesterol (mg/dL) 
 3.2 ± 1.1 
124.2 ± 42.0 
3.3 ± 1.1 
126.2 ± 44.0 
Hemoglobin-A1c (%)§ǁ  5.6 (5.3, 5.9) 5.6 (5.3, 5.9) 
Fasting plasma glucose (mmol/L) § 
Fasting plasma glucose (mg/dL) § 
 5.4 (5.0, 5.9) 
97.0 (90.0 106.0) 
5.4 (5.0, 5.9) 
97.0 (90.0, 107.0) 
Data shown as mean ± SD or count (%) 
* Race not specified for 1 participant 
† Defined as previously known T2DM, on glucose-lowering medication, baseline FPG ≥ 7.0 
mmol/L or baseline HbA1c ≥6.5% 
‡ Impaired fasting glucose (i.e. fasting plasma glucose 6.1–6.9mmol/L) or HbA1c ≥6.0% at 
baseline, and not meeting the criteria for T2DM 
§ Median (Q1, Q3) 
ǁ Available for 1991 participants assigned to control and 3149 assigned to evolocumab 
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Supplementary Table 3. Changes in Low Density Lipoprotein-cholesterol, fasting plasma glucose and Hemoglobin-A1c over 12 weeks in 
parent trials of evolocumab 
 
  LDL-C in mmol/L (mean ± SD for baseline [n]; 
mean ± SE for week 12 [n]) 
Fasting plasma glucose in mmol/L 
(median (Q1, Q3) [n]) 
HbA1c in % (median (Q1, Q3) 
[n]) 
  Any placebo Ezetimibe EvoMab Control EvoMab Control EvoMab 
All 
subjects 
 
Baseline  
3.1 ± 1.0 
[1728] 
3.7 ± 1.3 
[554] 
3.3 ± 1.1 
[4148] 
5.4 (5, 5.9) 
[2282 
5.4 (5, 5.9) 
[4148] 
5.6 (5.3, 5.9) 
[1991] 
5.6 (5.3, 5.9) 
[3149] 
Week 12 
3.1 ± 0.03 
[1577] 
3.0 ± 0.06 
[501] 
1.4 ± 0.02 
[3692] 
5.4 (5.1, 5.9) 
[2193] 
5.4 (5.1, 6) 
[3846] 
5.6 (5.3, 5.9) 
[2174] 
5.6 (5.3, 5.9) 
[3586] 
Change to Week 12 
0 ± 0.02 
[1577] 
-0.7 ± 0.03 
[501] 
-1.9 ± 0.01 
[3692] 
0 (-0.3, 0.3) 
[2193] 
0.1 (-0.3, 0.4) 
[3846] 
0.0 (-0.1, 0.2) 
[1932] 
0.0 (-0.1, 0.1) 
[3035] 
Diabetes 
 
Baseline  
2.8 ± 0.8 
[309] 
3.2 ± 1.2 
[78] 
3.0 ± 1.0 
[720] 
6.9 (5.9 7.9) 
[387] 
6.8 (5.9, 7.9) 
[720] 
6.6 (6.1, 7.2) 
[381] 
6.5 (6.0, 7.1) 
[614] 
Week 12 
2.7 ± 0.05 
[289] 
2.5 ± 0.13 
[66] 
1.2 ± 0.03 
[636] 
6.9 (5.9 8.2) 
[374] 
6.9 (6, 8.1) 
[660] 
6.6 (6.1, 7.2) 
[377] 
6.6 (6.0, 7.2) 
[616] 
Change to Week 12 
0 ± 0.04 
[289] 
-0.7 ± 0.09 
[66] 
-1.8 ± 0.03 
[636] 
0.1 (-0.4, 0.7) 
[374] 
0.1 (-0.6, 0.7) 
[660] 
0.1 (-0.1,0.3) 
[372] 
0.0 (-0.2, 0.3) 
[595] 
No 
Diabetes 
Baseline  
3.1 ± 1.0 
[1419] 
3.7 ± 1.3 
[476] 
3.3 ± 1.2 
[3428] 
5.3 (4.9, 5.7) 
[1895] 
5.3 (5, 5.7) 
[3428] 
5.5 (5.3, 5.7) 
[1610] 
5.5 (5.3, 5.7) 
[2535] 
Week 12 
3.2 ± 0.03 
[1288] 
3.0 ± 0.06 
[435] 
1.4 ± 0.02 
[3056] 
5.3 (4.9, 5.7) 
[1819] 
5.3 (5, 5.7) 
[3186] 
5.5 (5.3, 5.8) 
[1797] 
5.5 (5.3, 5.8) 
[2970] 
Change to Week 12 
0.1 ± 0.02 
[1288] 
-0.7 ± 0.04 
[435] 
-1.9 ± 0.02 
[3056] 
0 (-0.3, 0.3) 
[1819] 
0.1 (-0.2, 0.3) 
[3186] 
0.0 (-0.1, 0.2) 
[1560] 
0.0 (-0.1, 0.1) 
[2440] 
High risk 
for 
Baseline  
3.0 ± 1.0 
[531] 
3.6 ± 1.3 
[155] 
3.2 ± 1.1 
[1328] 
5.8 (5.6, 6.1) 
[686] 
5.8 (5.6, 6.1) 
[1328] 
5.7 (5.5, 6.0) 
[593] 
5.7 (5.5, 6.0) 
[1008] 
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diabetes* 
Week 12 
3.1 ± 0.05 
[492] 
2.9 ± 0.09 
[142] 
1.3 ± 0.02 
[1174] 
5.7 (5.4, 6.1) 
[667] 
5.7 (5.4, 6.1) 
[1232] 
5.7 (5.5, 6.0) 
[660] 
5.7 (5.4, 6.0) 
[1161] 
Change to Week 12 
0.1 ± 0.03 
[492] 
-0.7 ± 0.05 
[142] 
-1.9 ± 0.03 
[1174] 
-0.1 (-0.4, 0.2) 
[667] 
-0.1 (-0.4, 0.2) 
[1232] 
0.0 (-0.1, 0.2) 
[581] 
0.0 (-0.1, 0.1) 
[970] 
Enrolled 
into Osler 
 
Baseline  
3.1 ± 1.0 
[1278] 
3.7 ± 1.3 
[376] 
3.3 ± 1.2 
[3148] 
5.4 (5, 5.9) 
[1654] 
5.4 (5.1, 5.9) 
[3148] 
5.6 (5.3, 6.0) 
[1435] 
5.6 (5.3, 6.0) 
[2357] 
Week 12 
3.1 ± 0.03 
[1204] 
2.9 ± 0.07 
[353] 
1.4 ± 0.02 
[2895] 
5.4 (5.1, 5.9) 
[1631] 
5.4 (5.1, 6) 
[2995] 
5.6 (5.3, 6.0) 
[1600] 
5.6 (5.3, 5.9) 
[2772] 
Change to Week 12 
0 ± 0.02 
[1204] 
-0.7 ± 0.04 
[353] 
-2.0 ± 0.02 
[2895] 
0 (-0.3, 0.3) 
[1631] 
0.1 (-0.3, 0.3) 
[2995] 
0.0 (-0.1, 0.2) 
[1413] 
0.0 (-0.1, 0.1) 
[2313] 
Did not 
enrol into 
Osler 
Baseline  
3.1 ± 0.9 
[450] 
3.6 ± 1.3 
[178] 
3.1 ± 1.0 
[1000] 
5.3 (5, 5.8) 
[628] 
5.4 (5, 5.9) 
[1000] 
5.5 (5.3, 5.9) 
[556] 
5.6 (5.3,5.9) 
[792] 
Week 12 
3.2 ± 0.06 
[373] 
3.0 ± 0.10 
[148] 
1.4 ± 0.03 
[797] 
5.4 (5, 5.9) 
[562] 
5.4 (5.1, 5.9) 
[851] 
5.6 (5.3, 5.9) 
[574] 
5.6 (5.3, 5.9) 
[814] 
Change to Week 12 
0.1 ± 0.04 
[373] 
-0.6 ± 0.06 
[148] 
-1.8 ± 0.03 
[797] 
0.1 (-0.2, 0.4) 
[562] 
0.1 (-0.2, 0.4) 
[851] 
0.0 (-0.1, 0.2) 
[519] 
0.0 (-0.1, 0.2) 
[722] 
* Subset of those with no diabetes, defined as impaired fasting glycemia or HbA1c ≥ 6.0% at baseline 
SOC: standard of care; EvoMab: evolocumab; SD: standard deviation; SE: standard error 
To convert glucose to mg/dL, multiply by 18; to convert LDL-cholesterol to mg/dL, multiply by 38.6 
 
 
